摘要
目的评价索拉非尼治疗国人原发性肝癌的疗效和安全性。方法总结2008年1月至2009年8月应用索拉非尼治疗的37例原发性肝癌患者的临床资料,其中3例由于在服药后6周内死亡未进行肿瘤评价。结果28例采用RE-CIST标准评价,24例获稳定,4例进展;8例ECOG体力状况评分改善;不良反应一般在服药后1～2周左右出现,37例患者中10例发生3～4级的不良反应,因不能耐受不良反应而减少药物剂量者7例,另3例停药。药物不良反应在减少剂量的基础上对症支持治疗后大多可以缓解。结论索拉非尼可延长晚期原发性肝癌患者的肿瘤无进展生存时间,且耐受性良好,是治疗晚期原发性肝癌的新选择。
Objective To evaluate the efficacy and safety of sorafenib in treatment of hepatocellular carcinoma.Methods From Jan.2008,to Aug.2009,37 patients with hepatocellular carcinoma were treated with sorafenib;their clinical data were retrospective1y analyzed.Three patients died within 6 weeks after sorafenib treatment and were excluded from this study.Results Twenty-eight patients received more than once of tumor assessment with RECIST criteria after six weeks;24 patients had stable condition and 4 patients had progressive tumors.Eight patients had improved ECOG performance status.The adverse reaction usually occured at about 1-2 weeks after drug administration.Among all the patients in this study,10 patients had severe adverse reaction（grade 3-4）,7 out of 10 patients reduced their dose of sorafenib duing to adverse reaction and 3 out of 10 patients withdrawed the drug.Most of the adverse reaction of sorafenib could be relieved after reducing the dose of sorafenib and symptom-targeted treatment.Conclusion Sorafenib can prolong the non-progressive survival of hepatocellular carcinoma patients and is well tolerated;it might be a new choice for treatment of hepatocellular carcinoma.
出处
《临床肿瘤学杂志》
CAS
2010年第4期352-354,共3页
Chinese Clinical Oncology
关键词
索拉非尼
原发性肝癌
疗效
Sorafenib
Hepatocellular carcinoma
Efficacy
